QuidelOrtho Quarterly Income Statement
NASDAQ: QDELHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
QuidelOrtho revenue and earnings
In the quarter ended Jun 28, 2026, QuidelOrtho generated $630.9 million in revenue, up 2.8% from the same quarter a year earlier. QuidelOrtho reported a net loss of $92.9 million, compared with a loss of $255.4 million a year earlier. Gross margin was 43.3% (down from 44.8%) and operating margin -3.5%.
Diluted earnings per share came in at -$1.36.
Summary generated from market data by MetaCap's automated system. Methodology
QuidelOrtho income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-28 | Q1 20262026-03-29 | Q4 20252025-12-28 | Q3 20252025-09-28 | Q2 20252025-06-29 | Q1 20252025-03-30 | Q4 20242024-12-29 | Q3 20242024-09-29 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-10-01 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 630.90M | 619.80M | 723.60M | 699.90M | 613.90M | 692.80M | 707.80M | 727.10M | 637.00M | 711.00M | 742.60M | 744.00M |
| Revenue growth (YoY) | +2.77% | -10.54% | +2.23% | -3.74% | -3.63% | -2.56% | -4.69% | -2.27% | -4.22% | -15.97% | -14.30% | -5.08% |
| Cost of Revenue | 358.00M | 356.00M | 403.20M | 364.30M | 339.00M | 349.50M | 381.70M | 374.80M | 361.00M | 378.90M | 360.00M | 374.60M |
| Gross Profit | 272.90M | 263.80M | 320.40M | 335.60M | 274.90M | 343.30M | 326.10M | 352.30M | 276.00M | 332.10M | 382.60M | 369.40M |
| Operating Expenses | 294.70M | 295.60M | 386.70M | 1.04B | 455.60M | 310.70M | 426.50M | 337.30M | 393.50M | 2.09B | 342.50M | 343.10M |
| Research & Development | 48.70M | 44.90M | 45.80M | 41.50M | 45.70M | 53.20M | 47.30M | 55.90M | 56.30M | 59.20M | 59.30M | 61.50M |
| Selling, General & Admin | 189.70M | 199.30M | 194.40M | 186.90M | 178.00M | 187.00M | 187.50M | 186.40M | 188.20M | 204.70M | 187.60M | 194.10M |
| Operating Income | -21.80M | -31.80M | -66.30M | -704.80M | -180.70M | 32.60M | -100.40M | 15.00M | -117.50M | -1.76B | 40.10M | 26.30M |
| Interest Expense | 54.70M | 51.10M | 51.00M | 46.10M | 40.50M | 40.00M | 40.60M | 42.90M | 41.00M | 39.00M | — | — |
| Other Income (Expense) | -4.70M | 3.40M | 4.90M | -900.00K | -8.40M | -1.40M | 100.00K | -900.00K | -4.40M | -1.90M | -12.60M | -4.10M |
| Pretax Income | -81.20M | -79.50M | -112.40M | -756.90M | -229.60M | -8.80M | -140.90M | -28.80M | -162.90M | -1.80B | -9.20M | -15.50M |
| Income Tax | 11.70M | 12.30M | 18.30M | -23.90M | 25.80M | 3.90M | 37.50M | -8.90M | -15.20M | -92.90M | -16.20M | -2.80M |
| Net Income | -92.90M | -91.80M | -130.70M | -733.00M | -255.40M | -12.70M | -178.40M | -19.90M | -147.70M | -1.71B | 7.00M | -12.70M |
| Net Income growth (YoY) | — | — | — | — | — | — | -2648.57% | — | — | -3595.90% | -76.90% | -166.15% |
| EPS (Basic) | -1.36 | -1.35 | -1.95 | -10.78 | -3.77 | -0.19 | -2.54 | -0.30 | -2.20 | -25.50 | 0.11 | -0.19 |
| EPS (Diluted) | -1.36 | -1.35 | -1.95 | -10.78 | -3.77 | -0.19 | -2.54 | -0.30 | -2.20 | -25.50 | 0.11 | -0.19 |
| Shares Outstanding (Basic) | 68.30M | 68.20M | — | 68.00M | 67.70M | 67.50M | — | 67.30M | 67.10M | 66.90M | — | 66.90M |
| Shares Outstanding (Diluted) | 68.30M | 68.20M | — | 68.00M | 67.70M | 67.50M | — | 67.30M | 67.10M | 66.90M | — | 66.90M |
| EBITDA | 94.90M | 81.10M | 46.20M | -592.70M | -70.40M | 139.70M | 8.90M | 128.10M | -1.40M | -1.64B | 155.50M | 139.40M |
| Gross Margin | 43.26% | 42.56% | 44.28% | 47.95% | 44.78% | 49.55% | 46.07% | 48.45% | 43.33% | 46.71% | 51.52% | 49.65% |
| Operating Margin | -3.46% | -5.13% | -9.16% | -100.70% | -29.43% | 4.71% | -14.18% | 2.06% | -18.45% | -247.26% | 5.40% | 3.53% |
| Net Margin | -14.72% | -14.81% | -18.06% | -104.73% | -41.60% | -1.83% | -25.20% | -2.74% | -23.19% | -239.94% | 94.00% | -1.71% |
This table shows 12 quarterly periods of QuidelOrtho's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow QDEL's reporting calendar. What is a income statement?